Press release
Respiratory Syncytial Virus (RSV) Pipeline Assessment, 2023 | In-depth Insights Into the Clinical and Non-Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Emerging Therapies, and Treatment Algorithm | Key Companies - GlaxoSmithKline (G
Respiratory syncytial virus (RSV) is a common cause of respiratory tract infection, particularly in children. Nearly all children have been infected by age four years, many in the first year of life. Infection does not provide complete immunity, so reinfection is common, although usually less serious. It is responsible for more than 50,000 hospitalizations every year in the United States in children under the age of 5 years.
To improve the treatment scenario, globally, several major pharma and biotech giants such as GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, and others are actively working in the Respiratory syncytial virus therapeutics market.
"Respiratory Syncytial Virus Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Respiratory Syncytial Virus Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Respiratory Syncytial Virus (RSV) Pipeline Analysis
The report provides insights into:
- The report provides detailed insights into the key companies that are developing therapies in the Respiratory Syncytial Virus Market.
- The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Respiratory Syncytial Virus treatment.
- It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Respiratory Syncytial Virus market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Learn More About the Emerging Therapies and Evolving Treatment Algorithms:
https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Respiratory Syncytial Virus (RSV) Pipeline Drugs - Route of Administration
Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Molecule Type
Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Respiratory Syncytial Virus (RSV) Therapeutics Analysis
There are approx. 50+ key companies developing therapies for Respiratory Syncytial Virus (RSV). Currently, GlaxoSmithKline is leading the therapeutics market with its Respiratory Syncytial Virus (RSV) drug candidates in the most advanced stage of clinical development among all the key players.
The Leading Companies in the Respiratory Syncytial Virus (RSV) Therapeutics Market Include:
GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Cidara Therapeutics Inc, Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc, IDBiologics Inc, Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, and others.
Respiratory Syncytial Virus (RSV) Therapies Covered in the Report Include:
- GSK3844766A: GlaxoSmithKline
- Nirsevimab (MEDI-8897): MedImmune
- Sisunatovir: ReViral
And Many More
Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Respiratory Syncytial Virus Current Treatment Patterns
4. Respiratory Syncytial Virus - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Respiratory Syncytial Virus Late-Stage Products (Phase-III)
7. Respiratory Syncytial Virus Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Respiratory Syncytial Virus Discontinued Products
13. Respiratory Syncytial Virus Product Profiles
14. Respiratory Syncytial Virus Key Companies
15. Respiratory Syncytial Virus Key Products
16. Dormant and Discontinued Products
17. Respiratory Syncytial Virus Unmet Needs
18. Respiratory Syncytial Virus Future Perspectives
19. Respiratory Syncytial Virus Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
Address: 428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Respiratory Syncytial Virus (RSV) Pipeline Assessment, 2023 | In-depth Insights Into the Clinical and Non-Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Emerging Therapies, and Treatment Algorithm | Key Companies - GlaxoSmithKline (G here
News-ID: 2886317 • Views: …
More Releases from DelveInsight Business Research
Global Vaccine Contract Manufacturing Market Set for Strong Growth, Forecast to …
The global Vaccine Contract Manufacturing Market is poised for robust expansion, expected to grow at a steady compound annual growth rate (CAGR) of approximately 6.9% from 2025 to 2032, reaching an estimated valuation of USD 3.9 billion. This growth is driven by escalating vaccine demand, developments in biopharmaceutical innovation, and the critical role contract manufacturers play in rapid, scalable vaccine production in response to emerging infectious diseases worldwide.
Contract manufacturing organizations…
Patient Engagement Solutions Market is Expected to Reach USD 59.4 Billion by 203 …
The global Patient Engagement Solutions Market is poised for robust growth, projected to soar from USD 23,880.95 million in 2024 to an impressive USD 59,499.28 million by 2032. This surge is driven by a compelling CAGR of 12.15% during the forecast period from 2025 to 2032, fueled primarily by the rising prevalence of chronic diseases and accelerating technological innovations in healthcare delivery.
Explore how cutting-edge patient engagement solutions can improve outcomes…
Global Cerebrospinal Fluid Management Market to grow at a CAGR of 5.18% to reach …
According to DelveInsight's analysis, The cerebrospinal fluid (CSF) management market is mainly propelled by the increasing prevalence of neurological and cerebrospinal disorders, driving the demand for advanced CSF management solutions. Moreover, the global rise in trauma and accident cases is further boosting market growth, as healthcare professionals increasingly depend on these devices to manage complications associated with cerebrospinal fluid more effectively.
DelveInsight's "Cerebrospinal Fluid Management Market Insights, Competitive Landscape and Market…
Global Wound Debridement Devices Market to grow at a CAGR of 5.53% to reach USD …
According to DelveInsight's analysis, The increasing incidence of chronic and non-healing wounds, including diabetic foot ulcers, pressure ulcers, and venous leg ulcers, is driving the demand for wound debridement devices. These wounds require consistent and effective management to prevent infection and support healing. Moreover, the growing number of trauma cases resulting from accidents and surgical procedures has heightened the need for efficient wound cleaning and tissue removal solutions. In addition,…
More Releases for Respiratory
Prevalence Of Respiratory Diseases Fuels Demand For Respiratory Disposables: Key …
The Respiratory Disposables Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Respiratory Disposables Market Size During the Forecast Period?
The respiratory disposables market has seen rapid growth in recent years. It is expected to grow from $1.01 billion in 2024 to $1.15…
Transforming the Respiratory Monitoring Devices Market in 2025: Rising Incidence …
What Is the Expected Size and Growth Rate of the Respiratory Monitoring Devices Market?
The market size for respiratory monitoring devices has seen swift expansion in the recent past. The market's growth is projected to increase from $1.67 billion in 2024 to $1.87 billion in 2025, with a compound annual growth rate (CAGR) of 11.8%. A combination of factors such as the prevalence of respiratory ailments, an aging demographic, technological innovations,…
Transforming the Respiratory Monitoring Devices Market in 2025: Rising Incidence …
What Is the Expected Size and Growth Rate of the Respiratory Monitoring Devices Market?
The market size for respiratory monitoring devices has seen swift expansion in the recent past. The market's growth is projected to increase from $1.67 billion in 2024 to $1.87 billion in 2025, with a compound annual growth rate (CAGR) of 11.8%. A combination of factors such as the prevalence of respiratory ailments, an aging demographic, technological innovations,…
Molecular Respiratory Panels Market: Enhancing Accuracy and Speed in Respiratory …
Introduction
The global molecular respiratory panels market is rapidly evolving, driven by the need for faster, more accurate diagnostics in respiratory diseases. With respiratory infections and diseases becoming increasingly prevalent worldwide, accurate detection and timely diagnosis are critical to improving patient outcomes. Molecular respiratory panels, which utilize advanced molecular techniques like PCR (Polymerase Chain Reaction) and other nucleic acid-based methods, enable the rapid identification of pathogens responsible for respiratory conditions. These…
Tackling Respiratory Challenges: Lower Respiratory Tract Therapeutics Market 202 …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Lower Respiratory Tract Therapeutics Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $48.37 billion In…
Respiratory Assist Devices Market - Breathing Uninterrupted: Innovating Respirat …
Newark, New Castle, USA - new report, titled Respiratory Assist Devices Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Respiratory Assist Devices market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Respiratory Assist Devices market. The report offers an overview of…
